No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy

Background/Objectives Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) de...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2019-06, Vol.66 (6), p.e27681-n/a
Hauptverfasser:	Robinson, Katherine M., Yang, Wenjian, Karol, Seth E., Kornegay, Nancy, Jay, Dennis, Cheng, Cheng, Choi, John K., Campana, Dario, Pui, Ching‐Hon, Wood, Brent, Borowitz, Michael J., Gastier‐Foster, Julie, Larsen, Eric C., Winick, Naomi, Carroll, William L., Loh, Mignon L., Raetz, Elizabeth A., Hunger, Stephen P., Devidas, Meenakshi, Mardis, Elaine R., Fulton, Robert S., Relling, Mary V., Jeha, Sima
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics, Antineoplastic - therapeutic use Child Cohort Studies daunorubicin Daunorubicin - therapeutic use doxorubicin Female Follow-Up Studies Glucosephosphate Dehydrogenase - metabolism glucose‐6‐phospate dehydrogenase Humans Induction Chemotherapy leukemia Male Neoadjuvant Therapy Neoplasm, Residual - drug therapy Neoplasm, Residual - enzymology Neoplasm, Residual - pathology pharmacogenetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Risk Factors Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!